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MaOBJECTIVES This study assessed long-term outcome after transcatheter atrial septal defect (ASD) closure in older
patients, especially those older than 75 years of age.
BACKGROUND The clinical beneﬁts of transcatheter ASD closure in this aged population are controversial.
METHODS A total of 244 patients older than 50 years of age were divided into 3 groups according to age at procedure
(50 to 59 years: n ¼ 69; 60 to 74 years: n ¼ 120; 75 years and older: n ¼ 55). The primary endpoint was deﬁned as
all-cause mortality and hospitalization due to heart failure or stroke. Improvements in functional capacity and cardiac
remodeling after the procedure were also assessed.
RESULTS During a median follow-up of 36 months, mortality and hospitalization due to heart failure or stroke occurred
in 18 patients (7%). Among patients older than 75 years of age, 2 died of noncardiovascular disease, 2 were hospitalized
due to heart failure, and 1 had a stroke. More than 90% of patients older than 75 years of age did not experience these
events. Kaplan-Meier analysis showed that the event-free survival rate was not different among the 3 age groups
(log-rank test, p ¼ 0.780). New York Heart Association functional class and right ventricular/left ventricular end-diastolic
diameter ratio improved in patients older than 75 years of age, similar to the other age groups.
CONCLUSIONS Long-term outcome after transcatheter ASD closure in patients older than 75 years of age is similar
to that in the other, relatively younger age groups. This suggests that transcatheter ASD closure can be considered a
valuable therapeutic option in patients older than 75 years of age. (J Am Coll Cardiol Intv 2015;8:600–6)
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failure, pulmonary artery hypertension, and atrial ar-
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AB BR E V I A T I O N S
AND ACRONYM S
ASD = atrial septal defect
BNP = B-type natriuretic
peptide
E = early diastolic mitral
valve ﬂow velocity
e0 = early diastolic septal
mitral annular velocity
LV = left ventricular
NYHA = New York Heart
Association
RV = right ventricular
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601regarding the clinical beneﬁts in this aged population.
A few studies have shown the short-term beneﬁts of
improvement in functional capacity and cardiac
remodeling after transcatheter ASD closure in older
patients (1,2,8–11). With regard to long-term outcome,
Kotowycz et al. (12) reported that transcatheter
closure was equivalent to surgical closure in adult
patients younger than 75 years of age. However, little
is known about the long-term outcome, deﬁned as
mortality and hospitalization due to heart failure, in
older patients, especially those older than 75 years of
age. Therefore, this study aimed to focus on older
patients, especially those older than 75 years of age,
and to assess the beneﬁts of transcatheter ASD
closure for the long-term outcome.SEE PAGE 607METHODS
STUDY POPULATION. The study population con-
sisted of 244 consecutive patients older than 50 years
of age (range 50 to 84 years; 151 females) who un-
derwent transcatheter ASD closure between April
2005 and November 2013. Because the survival rate in
young adult patients was similar to that in age-
matched controls (13), we included patients older
than 50 years of age in the present study. To assess
the beneﬁts of transcatheter ASD closure for the long-
term outcome in older patients, especially patients
older than 75 years of age, compared with those in
patients between 50 and 59 years of age who were a
relatively younger age group, patients were divided
into 3 groups according to age at the procedure: 69
were patients between 50 and 59 years of age, 120
patients were between 60 and 74 years of age, and 55
patients older than 75 years of age.
Indications for transcatheter ASD closure were a
signiﬁcant left-to-right shunt, right ventricular (RV)
volume overload, and/or clinical symptoms of heart
failure or paradoxical embolism. Exclusion criteria
included pulmonary hypertension with pulmonary
vascular resistance >8 Wood units in the reversibility
test using 100% oxygen and other concomitant
congenital heart disease. All of the patients gave writ-
ten informed consent for the procedure. The studywas
approved by the ethics committee of our institution.
TRANSCATHETER ASD CLOSURE. Transcatheter ASD
closure was performed, as described previously (14),
using the Amplatzer Septal Occluder (St. Jude
Medical, St. Paul, Minnesota). Before the procedure,
the pulmonary-to-systemic blood ﬂow ratio and pul-
monary artery pressure were evaluated with cardiac
catheterization. For patients who were considered tobe hemodynamically high risk, such as those
with pulmonary artery hypertension or heart
failure, pulmonary artery wedge pressure was
monitored just before the release of the de-
vice. All of the patients received 100 mg/day
of aspirin at least 48 h before the procedure,
which was continued for 6 months after the
procedure. Clopidogrel was also administered
at a dose of 50 to 75 mg/day for 1 month after
the procedure. Other medications, such as
diuretic and antihypertension drugs, were
continued.
STUDY DESIGN. This was a retrospective
cohort study. The primary endpoint was deﬁned as
all-cause mortality and hospitalization due to heart
failure or stroke. The secondary endpoint was deﬁned
as cardiovascular mortality and hospitalization due to
heart failure or stroke. Improvement in functional
capacity and cardiac remodeling evaluated by trans-
thoracic echocardiography at the latest follow-up was
also assessed. Patients were followed from the date of
the procedure until the date of ﬁrst documentation of
mortality and hospitalization or the end of follow-up,
whichever occurred ﬁrst. Follow-up information was
obtained by medical records, contact with the pa-
tient’s physicians, or telephone interview with the
patient or, if deceased, with family members.
CLINICAL ASSESSMENTS. Clinical assessments were
scheduled at 1 month and 3, 6, and 12 months after the
procedure and annually thereafter. New York Heart
Association (NYHA) functional class and plasma B-
type natriuretic peptide (BNP) levels were assessed.
Transthoracic echocardiography was also performed.
LV end-diastolic and end-systolic diameters and
RV end-diastolic diameter were measured by 2-
dimensional parasternal long-axis views. LV ejection
fraction was derived using Teichholz’s formula. Early
E (diastolic mitral valve ﬂow velocity) and e0 (early
diastolic septal mitral annular velocity) were
measured by pulsed wave Doppler and tissue Doppler
imaging, respectively. An average of more than 5 de-
terminations of each variable was assessed by 2 in-
dependent cardiologists.
STATISTICAL ANALYSIS. Data are presented as
mean  SD for continuous variables and as number
and percentage for categorical variables. Continuous
variables were compared among the 3 age groups by
1-way analysis of variance for normal distribution
variables and by the Kruskal-Wallis test for non-
normal distribution variables. Categorical variables
were compared by the chi-square test and Fisher exact
test. Differences between baseline and follow-up in
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602each age group were analyzed by the paired Student
t test and theWilcoxon signed rank test. The event-free
survival rate was estimated by Kaplan-Meier analysis,
and the difference was compared by the log-rank test.
Statistical analysis was performed with JMP version
8.0 (SAS Institute Inc., Cary, North Carolina), and sig-
niﬁcance was deﬁned as p < 0.05.
RESULTS
BASELINE CHARACTERISTICS. Comparison of base-
line characteristics among the 3 age groups is shown
in Table 1. As expected, patients older than 75 years of
age had more comorbidities, such as hypertension,
permanent atrial ﬁbrillation, and stroke. Among pa-
tients older than 75 years or age, 14 (25%) were in
NYHA functional class III/IV, 21 (38%) had a history of
hospitalization due to heart failure, and 32 (58%)
were being treated with diuretic agents for heart
failure before the procedure. The severity of heart
failure was greater in patients older than 75 years of
age. Lower e0 and higher E/e0 were observed in pa-
tients older than 75 years of age.TABLE 1 Comparison of Baseline Characteristics Among Age Groups
All
(N ¼ 244)
50
(n
Age, yrs 66  9 5
Female 151 (62) 4
ASD diameter, mm 19  7 (4–38) 20 
Device size, mm 22  7 (8–38) 23 
Pulmonary-to-systemic blood ﬂow ratio 2.6  0.8 2.
Pulmonary artery pressure, mm Hg 17  6 1
Hypertension 91 (37) 1
Diabetes mellitus 35 (14)
Permanent atrial ﬁbrillation 42 (17)
Stroke 19 (8)
Coronary artery disease 15 (6)
Smoking 36 (15) 1
NYHA functional class I/II 217 (89) 6
NYHA functional class III/IV 27 (11)
Hospitalization due to heart failure 37 (15)
Diuretic agent use 87 (36) 1
B-type natriuretic peptide, pg/ml 119  166 5
LV end-diastolic diameter, mm 41  5 4
LV end-systolic diameter, mm 25  4 2
LV ejection fraction, % 70  6 6
RV end-diastolic diameter, mm 38  6 3
RV/LV end-diastolic diameter ratio 0.93  0.19 0.9
e0, cm/s 8.6  2.4 9
E/e0 ratio 8.9  3.0 8.
Hospital stay after the procedure, days 3  2
Median follow-up period, months 34
Values are mean  SD, n (%), or mean  SD (range).
ASD ¼ atrial septal defect; E ¼ early diastolic mitral valve ﬂow velocity; e0 ¼ early di
Association; RV ¼ right ventricular.MORTALITY AND HOSPITALIZATION. During a me-
dian follow-up of 36 months (range 1 to 104 months),
mortality and hospitalization due to heart failure or
stroke occurred in 18 patients (7%) (Table 2). Of pa-
tients between 50 and 59 years of age, 2 were hospi-
talized due to heart failure, and 2 had a stroke. Of
patients between 60 and 74 years of age, 1 died of a
stroke, 3 died of cancer, 1 died of amyotrophic lateral
sclerosis, and 1 died of an unknown cause at home at
3 months after the procedure. In the patient who died
of an unknown cause, a history of transient cerebral
ischemic attack was reported at 1 week before the
death. The remaining 3 patients were hospitalized
due to heart failure. Of patients older than 75 years of
age, 1 died of cancer, 1 died of chronic obstructive
pulmonary disease, 2 were hospitalized due to heart
failure, and 1 had a stroke. The incidence of mortality
and hospitalization was not different among the 3 age
groups (6%, 8%, and 9%; p ¼ 0.781). More than 90% of
patients older than 75 years of age did not experience
these events. Kaplan-Meier analysis showed that the
event-free survival rate was not different among the
3 age groups (log-rank test, p ¼ 0.780) (Figure 1).–59 Yrs
¼ 69)
60–74 Yrs
(n ¼ 120)
$75 Yrs
(n ¼ 55) p Value
5  3 66  4 78  3 <0.001
9 (71) 70 (58) 32 (58) 0.175
8 (5–38) 19  7 (4–38) 19  8 (4–38) 0.777
7 (8–38) 22  6 (8–38) 23  7 (11–38) 0.366
7  0.9 2.5  0.8 2.6  0.8 0.347
6  8 18  5 18  5 0.146
7 (25) 49 (41) 25 (45) 0.028
5 (7) 20 (17) 10 (18) 0.106
2 (3) 17 (14) 23 (42) <0.001
3 (4) 7 (6) 9 (16) 0.040
1 (1) 8 (7) 6 (11) 0.061
1 (16) 17 (14) 8 (15) 0.946
8 (99) 108 (90) 41 (75) <0.001
1 (1) 12 (10) 14 (25)
4 (6) 12 (10) 21 (38) <0.001
7 (25) 38 (32) 32 (58) <0.001
3  76 94  88 255  271 <0.001
1  5 42  5 41  5 0.175
5  4 25  5 24  3 0.442
9  6 70  7 71  6 0.472
7  6 38  5 40  6 0.024
1  0.19 0.92  0.17 0.98  0.22 0.086
.7  2.1 8.2  2.3 8.0  2.6 <0.001
0  2.2 8.9  2.9 10.2  3.6 <0.001
3  3 3  2 4  3 0.004
39 30 36 0.381
astolic septal mitral annular velocity; LV ¼ left ventricular; NYHA ¼ New York Heart
FIGURE 1 All-Cause Mortality and Hospitalization
Survival rate without all-cause mortality and hospitalization due to heart failure or stroke
after transcatheter atrial septal defect closure according to age. Dashed lines represent
the 95% conﬁdence interval of survival rate.
TABLE 2 All-Cause Mortality and Hospitalization Due to Heart Failure or Stroke After
Transcatheter Atrial Septal Defect Closure
Age, yrs Sex
Follow-Up,
months
All-Cause Mortality and Hospitalization Due to
Heart Failure or Stroke
52 F 14 Heart failure
55 F 3 Stroke
56 F 12 Stroke
59 M 6 Heart failure
63 M 3 Death (stroke)
63 M 18 Death (amyotrophic lateral sclerosis)
65 F 4 Heart failure
66 F 2 Heart failure
66 F 3 Heart failure
68 M 21 Death (lung cancer)
68 F 30 Death (hepatic cancer)
71 F 3 Death (unknown)
71 M 7 Death (hepatic cancer)
76 M 4 Heart failure
77 M 42 Death (chronic obstructive pulmonary disease)
78 M 16 Heart failure
82 M 20 Death (prostatic cancer)
83 F 41 Stroke
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603When the secondary endpoint deﬁned as cardio-
vascular mortality and hospitalization due to heart
failure or stroke was assessed, Kaplan-Meier analysis
showed that the event-free survival rate in pa-
tients older than 75 years of age was equal to that in
the other age groups (log-rank test, p ¼ 0.938)
(Figure 2).
No deaths related to transcatheter ASD closure
were observed. There were no major complications
related to the procedure. Erosion, device emboliza-
tion, or thrombus formation was not observed during
the follow-up period. Acute congestive heart failure
immediately after the procedure, which required
additional treatment, such as intravenous adminis-
tration of inotropes and mechanical support, did not
occur in patients older than 75 years of age.
FUNCTIONAL CAPACITY AND CARDIAC REMODELING.
After the procedure, NYHA functional class improved
in 28 (62%) of 45 patients older than 75 years of age of
NYHA functional class II or III. No patients had
deterioration of NYHA functional class (Figure 3).
Plasma BNP levels signiﬁcantly decreased, even in
patients older than 75 years of age. RV end-diastolic
diameter decreased, LV end-diastolic diameter
increased, and RV/LV end-diastolic diameter ratio
signiﬁcantly improved in patients older than 75 years
of age, similar to the other age groups (Table 3). A
small residual shunt evaluated by transthoracic
echocardiography was observed in 3 patients (4%)
between 50 and 59 years of age, in 7 (6%) patients
between 60 and 75 years of age, and in 4 patients (7%)
older than 75 years of age. However, no patients had
moderate or severe residual shunt.
DISCUSSION
The major ﬁndings of the present study are as fol-
lows: 1) more than 90% of patients older than 75 years
of age did not have all-cause mortality and hospital-
ization due to heart failure or stroke during the
follow-up period; 2) the long-term outcome in pa-
tients older than 75 years of age was not different
from that in the other age groups; and 3) functional
capacity and cardiac remodeling improved in patients
older than 75 years of age, similar to the other age
groups. To the best of our knowledge, this is the ﬁrst
study to show the long-term outcome, deﬁned as
mortality and hospitalization, after transcatheter ASD
closure in older patients.
Because older patients are at high risk of
mortality and morbidity, their outcome is considered
to be inferior compared with that in young adult pa-
tients in whom the survival rate after ASD closure issimilar to that in age-matched controls (13). There-
fore, the present study included patients older than
50 years of age except for young adult patients
and assessed the outcome in patients older than
75 years of age compared with that in the other rela-
tively younger age groups. In addition, the primary
FIGURE 2 Cardiovascular Mortality and Hospitalization
Survival rate without cardiovascular mortality and hospitalization due to heart failure or
stroke after transcatheter atrial septal defect closure according to age. Dashed lines
represent the 95% conﬁdence interval of survival rate.
FIGURE 3 Functional Capacity
New York Heart Association functional class according to age.
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604endpoint of the present study included non-
cardiovascular death to assess the beneﬁts of trans-
catheter ASD closure in the real-world setting.
OUTCOME. Although most studies have shown the
beneﬁts of transcatheter ASD closure (3–7,15), the
data for older patients are limited. Because not only
surgical closure but also transcatheter closure have
been reported but with limited experience in older
patients, ASD closure may be considered as non-
beneﬁcial in this older population. More recently, a
few studies have shown the short-term beneﬁts of
transcatheter ASD closure in older patients, including
improvement in functional capacity and cardiac
remodeling (1,2,8–11). However, limited information
is available regarding the long-term outcome,
deﬁned as mortality and hospitalization, in this older
population.
The present study showed that the survival rate
without all-cause mortality and hospitalization in
patients older than 75 years of age was not equal to
that in the other age groups. However, 2 patients
died of noncardiovascular events related to age,
and the cause of stroke in 1 patient was considered
to be arteriosclerosis, but not related to the proce-
dure or the device, as was diagnosed by neurolo-
gists using magnetic resonance imaging. The
difference in the survival rate was probably caused
by the age-related events. Furthermore, althoughw40% of patients older than 75 years of age had
a history of hospitalization due to heart failure
before the procedure, only 2 were hospitalized after
the procedure. Therefore, our ﬁndings suggest that
transcatheter ASD closure is effective for preventing
TABLE 3 Clinical Assessments Before and After Transcatheter Atrial Septal Defect Closure
50–59 yrs (n ¼ 69) 60–74 yrs (n ¼ 120) $75 yrs (n ¼ 55)
Before After p Value Before After p Value Before After p Value
B-type natriuretic peptide, pg/ml 53  76 33  27 0.055 94  88 64  55 0.003 255  271 135  123 0.005
LV end-diastolic diameter, mm 41  5 44  4 <0.001 42  5 46  4 <0.001 41  5 45  4 <0.001
RV end-diastolic diameter, mm 37  6 30  6 <0.001 38  5 31  5 <0.001 40  6 33  5 <0.001
RV/LV end-diastolic diameter ratio 0.91  0.19 0.68  0.16 <0.001 0.92  0.17 0.68  0.13 <0.001 0.98  0.22 0.75  0.13 <0.001
Values are mean  SD.
Abbreviations as in Table 1.
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605cardiovascular events related to ASD, even in pa-
tients older than 75 years of age. In addition,
NYHA functional class and RV/LV end-diastolic
diameter ratio improved, even in these patients,
despite long-standing volume overload. Improve-
ment in functional capacity and cardiac remodeling
can be expected irrespective of age.
COMPLICATIONS RELATED TO ASD CLOSURE.
Surgical ASD closure has a low risk but is obviously
associated with perioperative mortality (13). Surgical
ASD closure also requires a prolonged hospital stay
and may cause psychological trauma, both of which
are related to a decrease in functional capacity in
older patients. Because age is found to be a predictor
of surgical mortality and complications, it is likely
that surgical closure should not be performed
routinely in older patients (13,16,17). However, the
present study showed that in patients older than
75 years of age, neither death nor major complica-
tions were related to transcatheter ASD closure.
Furthermore, NYHA functional class improved in
these patients. Therefore, our ﬁndings suggest that
transcatheter ASD closure is safe and contributes to
improvement of quality of life, even in patients older
than 75 years of age.
LV diastolic dysfunction, which is common in
older patients, often causes the development of
acute congestive heart failure immediately after ASD
closure because of an abrupt increase in LV preload
(18,19). However, in the present study, acute
congestive heart failure immediately after the pro-
cedure was not observed in any of patients older
than 75 years of age, although they had LV diastolic
dysfunction as estimated by a decrease in e0 (20).
Anticongestive medications were reported to be
effective for preventing acute congestive heart fail-
ure after ASD closure (19). In our series, more than
one-half of patients older than 75 years of age were
being treated with diuretic agents before ASD
closure, indicating that strict volume management
before the procedure might contribute to theprevention of acute congestive heart failure in this
older population.
CLINICAL IMPLICATIONS. At the time when surgical
closure was the only approach for ASD, older patients
tended to refuse or hesitate to undergo ASD closure.
This was considered to be mainly because of the risk
of open heart surgery with cardiopulmonary bypass.
Indeed, in the present study, approximately one-half
of patients older than 75 years of age had previously
had a diagnosis of ASD, but they had refused surgical
closure. From this point of view, transcatheter ASD
closure may be more acceptable for older patients
because it has therapeutic advantages, including
being less invasive with fewer complications and
shorter hospital stay (5–7). However, in the clinical
setting, even attending physicians cannot decide
whether transcatheter ASD closure should be per-
formed in older patients because of the lack of sci-
entiﬁc evidence. Therefore, ASD closure is often
delayed or withheld in this older population, despite
the development of congestive heart failure. The
present study showed that transcatheter ASD closure
can be safety performed and contributes to long-term
clinical beneﬁts in patients older than 75 years of age.
Our ﬁndings suggest that transcatheter ASD closure
should be performed without age limitation and that
age should not be a factor to exclude candidates. The
present study provides evidence that transcatheter
ASD closure can be a valuable therapeutic option,
even in patients older than 75 years of age.
STUDY LIMITATIONS. The major limitation of this
study is relatively small number of patients. This was
a retrospective cohort study with no control group. A
large randomized, prospective study is required to
conﬁrm the beneﬁts of transcatheter ASD closure in
older patients. In addition, this study excluded young
adult patients. The long-term outcome in older pa-
tients was not compared with that of young adult
patients. Another limitation is that the assessment
of functional capacity was made on the basis of the
PERSPECTIVES
The clinical beneﬁts of transcatheter closure of
ASD in older patients are still unclear. This study
demonstrated that the long-term outcome after
transcatheter ASD closure in patients older than 75
years of age is similar to that in the other relatively
younger age groups. Our data suggest that trans-
catheter ASD closure is a valuable therapeutic op-
tion, even in older patients.
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606patient’s subjective impression, but not oxygen up-
take as evaluated by cardiopulmonary exercise
testing. However, performance on cardiopulmonary
exercise testing is affected by lower extremity muscle
weakness in older patients, and, therefore, the
improvement in NYHA functional class was regarded
as an improvement in functional capacity in the pre-
sent study.
CONCLUSIONS
The long-term outcome after transcatheter ASD
closure in patients older than 75 years of age is similar
to that in the other relatively younger age groups.
Improvement in functional capacity and cardiac
remodeling occurs even in patients older than 75
years of age, similar to the other age groups. Our
ﬁndings suggest that the transcatheter ASD closure
can be considered a valuable therapeutic option in
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